Eyquem Fund LP systematically targets
stocks at the largest discount from their full change ‐ of ‐ control value with the highest probability of undergoing a near ‐ term catalytic change ‐ of ‐ control event.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of
discount required on Gilead's products; an increase in
discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a
larger than anticipated shift in payer mix to more highly
discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or
at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its
stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Since 1970, their average P / E multiple has been about two - thirds of the S&P, and 90 % of the time utility
stocks have sold
at a
larger discount than they do today.
We do believe, however, that business values increased more than
stock prices, so we begin 2012 enthusiastic that
stocks are now priced
at an even
larger discount to our value estimates.
Here's how it worked: You commit to accumulating
large blocks of shares of a Hong Kong - listed
stock every day for, say, 12 months
at a
discount to the share price when you sign up.
When a management believes that it is acquiring a business
at a
larger discount to value than its own
stock sells
at, we are happy to see our capital spent on acquisitions.
In 2000, technology
stocks traded
at huge valuation premiums; today they sell
at large discounts.
That is, acting on the fact that
larger, well - known companies were recently trading
at steep
discounts to historical prices, portfolio managers dumped their illiquid, ignominious
stocks and rushed into these more popular but depressed
stocks.
In short, you'd have the opportunity to 1) capture a double - digit annualized yield or 2) pick up a high quality dividend growth
stock at an even
larger discount than what it's already trading for.
Consumer Discretionary
stocks are trading
at the
largest discount to their median P / S ratio.
Dividends4Life presents Wal - Mart Stores, Inc. (WMT) Dividend
Stock Analysis posted
at Dividend Growth
Stocks, saying, «Wal - Mart Stores, Inc. is the
largest retailer in North America and operates a chain of
discount department stores, wholesale clubs, and combination
discount stores and supermarkets.
They excel
at measuring the intrinsic values of companies and waiting patiently until the
stocks that they fancy sell
at large discounts to those intrinsic values.
For my company (
large international software firm) I am allowed to buy company
stock at a
discounted price.
Common
stocks in the TAVF portfolio that appear to be $ 100 bills bought
at large discounts include the following:
Value
stocks» outperformance is even more pronounced for small and mid cap companies, because they tend to trade
at even bigger
discounts due to illiquidity and lack of analyst coverage, as well as being able to achieve higher growth rates than
larger companies.
Many
larger companies offer a
stock purchasing plan, and
at a
discount as well!
Any value investor likes to pounce on a
stock which trades
at a
large discount to asset value.
«Individuals are thus better off finding value in the analyst - ignored small cap universe where
stock prices are the most inefficient and where companies trading
at large discounts can be found.»
I'd heard about JDS employees who bought
stock at huge
discounts (and thus
large tax bills), then watched the
stock tank.
That's because to a
large extent, successful value investors never buys
stocks, they buy long term values
at an intrinsic
discount to their earning potential.
Further, the
largest potential beneficiaries from dividend tax relief might be those who own common
stocks selling
at a
discount from, or a small premium over, the amount of tax paid earnings retained after year 2000.